A narrative chronicle about software that dissects pandemics, genomes and health economies
One Tuesday at dawn, in the basement of the Pasteur Institute in Dakar, virologist Oumar Ndiaye drops a test strip onto the steel table.
Within seconds, her laptop vibrates: Foundry has finished aligning 63,000 viral sequences from five continents.
The algorithm flags in red a pattern of mutations that, according to the dashboard legend, increases the virus's affinity for lung receptors by 18%.
Oumar takes a sip of coffee and presses “alert.” Four thousand five hundred kilometers away, in a room at the ECDC in Stockholm, her warning arrives stamped “critical priority.” An invisible thread connects two laboratories and shrinks the world until it fits on a microbiologist's screen.
This is how our chapter begins: Palantir's incursion into living tissue—medical, genomic, pharmaceutical—and the dilemma of how much health we are willing to entrust to a graph.
COVID-19: the first major health case
The immunological baptism: COVID-19 and the dashboard that never slept.
April 2020. The United Kingdom, exhausted, creates the NHS Data Store with Foundry as its engine.
What began as a count of beds and ventilators mutated into an almost organic map of the health system: ICU listings, dexamethasone stocks, oxygenation rates by municipality. Every dawn, a priority algorithm reordered ambulances; every midnight, it proposed transfers to avoid overloads.
A paper in The Lancet estimated that the redistribution of resources saved between 7,000 and 9,500 lives.
The success sealed Palantir's entry into applied epidemiology; the ethical debate had barely warmed up its engines.
Genomes, hospitals and orphan drugs
Genomes as passports: the Reykjavík adventure.
Iceland, 2022. The sequencing company deCODE uploads 400,000 genomes—more than 90% of the population—to Foundry to correlate rare variants with cardiovascular risk.
The government imposes two locks: total anonymity and a ban on police use. The software generates a heatmap of risk alleles that is overlaid on dietary habits, postal address and microplastic concentration in water.
A rural doctor discovers that the LPA KIV-2 mutation, associated with heart attacks, spikes in fjords with high consumption of smoked meat. Radio stations talk about “geographic genetics”; critics respond that the oracle has just handed them a map for discriminating in life insurance.
Clinics on autopilot: the Mayo-Pal case:
In Rochester, the Mayo Clinic launches Mayo-Pal, a digital twin of its seven hospitals.
Every drop of contrast dye, every monitored heartbeat feeds a graph that predicts bottlenecks in operating rooms and colonizes surgeons' schedules. A resident awake at two in the morning asks the system: “How many minutes would I save if I swap the atrial ablation with laparoscopy 3?”
Foundry calculates; Apollo patches schedules; the head nurse receives on her beeper a change that saves 14 minutes and $2,000 in anesthesia. The efficiency dazzles, until an anesthesiologist notices that the algorithm relegates surgeries of patients with less insurance coverage to night shifts. The administration claims “resource optimization”; the unions announce a lawsuit over socioeconomic bias.
Pharmaceuticals and orphan molecules:
Pfizer, Novartis and two emerging biotechs share a “blind consortium” with Palantir to speed up orphan drugs. Each company uploads encrypted preclinical data; Foundry queues it in silos that reveal only statistical patterns.
One day a correlation appears between a kinase inhibitor and an ultra-rare subtype of childhood cancer. Within 72 hours, the draft clinical protocol is ready. The agreement is that any finding is divided in royalties according to data contribution. But how do you measure who supplied the decisive thread? A Swiss lawyer sums up the uncertainty this way: “The discovery belongs to everyone and to no one; but the trial bill arrives tomorrow.”
Dengue and precision nutrition: public health with data
Epidemiological surveillance: the mosquito radar:
Singapore, 2024. The Ministry of Health attaches sensors to urban flowerpots to measure Aedes aegypti larvae.
The data flows to Gotham, which integrates repellent sales, tweets containing the word “fever” and construction permits to forecast dengue outbreaks. The algorithm suggests fumigating two blocks of Geylang and postponing work on an elevated metro line.
The contractor protests: “Every day of delay is worth $1 million.” The city council obeys the software; the press asks who will compensate the consortium. An epidemiologist sums up the debate: “It's the first time a mosquito has won a public works bid.”
Low-calorie data: precision nutrition in São Paulo.
In a São Paulo supermarket, a customer scans a processed meat.
The Ministry of Health's app, backed by AIP, cross-references his genotype (if he agrees to share it), his medical history and the product's sodium content. Then it paints a traffic light: green, yellow or red.
Sales shift; brands reformulate their recipes. The industry applauds the personalized guidance until AIP begins to suggest taxes differentiated by cardiometabolic risk. Legislators speak of an “Orwellian diet”; nutritionists celebrate the drop in sugar. The line between nudge and coercion blurs at the pace of the shopping cart.
Clinical trials, biosecurity and transplants
Digital trials and a placebo of bits:
Oxford, 2025. A study on multiple sclerosis recruits patients through a mobile app. Foundry assigns placebo or treatment according to genomic strata and biomarkers in saliva. The adaptive design cuts the sample in half and speeds up regulatory approval. However, a biostatistician detects that the algorithm eliminated, as outliers, carriers of mixed African-European ancestry.
The bias threatens to leave a minority without evidence. Palantir publishes a bug-fix and adds a real-time diversity panel. The lesson is uncomfortable: the software that shortens trials can also shrink representativeness.
CRISPR hackers and the post-quantum lock:
Gene editing is democratized; a clandestine laboratory in Shenzhen leaks a plasmid with resistance to antivirals. Interpol activates Gotham-BioShield, a module trained to track orders for DNA synthesizers and cryptocurrency movements.
Within 36 hours, the network falls; on Twitter the word “cyber-eugenics” appears. Critics fear that an algorithm with access to genetic samples could mistake legitimate research for bioterrorism.
Palantir responds with post-quantum encryption and outside audits. A journalist concludes: “Biosecurity no longer fits in vials; now it lives in ones and zeros that never sleep.”
The organ market and the ethics of the graph:
India, 2025. A public hospital integrates its transplant waiting list into Foundry.
The algorithm, neutral in appearance, uncovers organ tourism routes and suspicious patterns in altruistic donations.
In exposing the scheme, it also reveals the identities of living donors protected by law. The press erupts; the government blocks the dashboard. Doctors want the tool; legislators fear leaks. The paradox is put this way: the graph that uncovers corruption also strips bare medical secrets. Where to draw the line between transparency and privacy when life or death beats in every edge?
Epilogue: silicon heartbeats, flesh pulses.
Let's return to Dakar. Oumar's alert triggers a video call with Stockholm, Atlanta and Canberra.
It is decided to raise the global risk level.
Ten minutes later, airports reschedule flights, veterinarians inspect farms and the WHO issues a lukewarm but attentive statement.
No one remembers when a microbe required so little bureaucracy to move governments. Nor is it clear who gets the credit: the virologist who pressed enter, the algorithm that threaded together the mutations or the old router that kept the data packet alive all the way to Sweden.
Public health is entering an era in which digital agility outpaces political inertia. Palantir sells speed; states buy hope.
But every line of code that heals can also classify, segregate or expose.
Between the virus and the graph beats a question with no definitive antibodies: when biology is written in SQL, can one extra parenthesis decide who breathes tomorrow?
